Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6045448 | 0.98 | OPRM1 (0.41) | OPRM1SIGMAR1KCNH2CHRM2CHRM3 | |
| SCHEMBL6045551 | 0.92 | OPRM1 (0.43) | OPRM1SIGMAR1KCNH2CHRM2CHRM3 | |
| SCHEMBL6045648 | 0.92 | OPRM1 (0.47) | OPRM1SIGMAR1KCNH2ACHEOPRD1 | |
| SCHEMBL6045524 | 0.91 | CHRM2 (0.44) | SIGMAR1CHRM2CHRM3ACHEALDH1A1 | |
| Oxalic Acid SCHEMBL6045481 | 0.91 | KDM4E (0.42) | OPRM1SIGMAR1KCNH2CHRM2CHRM3 | |
| SCHEMBL6045530 | 0.90 | ALDH1A1 (0.44) | OPRM1SIGMAR1CHRM2CHRM3OPRD1 | |
| Oxalic Acid SCHEMBL6045490 | 0.90 | OPRM1 (0.46) | OPRM1SIGMAR1KCNH2ACHEOPRD1 | |
| SCHEMBL6045779 | 0.90 | CHRM2 (0.40) | OPRM1SIGMAR1CHRM2CHRM3ALDH1A1 | |
| Oxalic Acid SCHEMBL6045775 | 0.90 | CHRM2 (0.43) | SIGMAR1CHRM2CHRM3ACHEALDH1A1 | |
| Oxalic Acid SCHEMBL6045777 | 0.89 | ALDH1A1 (0.43) | OPRM1SIGMAR1CHRM2CHRM3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | OPRM1 148/4885SIGMAR1 179/4885KCNH2 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.